David Goldstein Sells 2,596 Shares of Alumis (NASDAQ:ALMS) Stock

Alumis Inc. (NASDAQ:ALMS) insider David Goldstein sold 2,596 shares of Alumis stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $68,456.52. Following the transaction, the insider owned 30,970 shares in the company, valued at $816,678.90. This represents a 7.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Alumis Price Performance

NASDAQ:ALMS opened at $27.80 on Friday. The firm has a market capitalization of $3.54 billion, a price-to-earnings ratio of -14.04 and a beta of -0.69. Alumis Inc. has a one year low of $3.76 and a one year high of $31.35. The business has a fifty day moving average price of $25.50 and a 200-day moving average price of $25.25.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The company had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. On average, equities research analysts expect that Alumis Inc. will post -2.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “neutral” rating and set a $25.00 price objective on shares of Alumis in a research report on Monday. Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Citigroup reaffirmed a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Morgan Stanley reiterated an “overweight” rating and issued a $39.00 price target on shares of Alumis in a research report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.30.

Institutional Trading of Alumis

Hedge funds have recently bought and sold shares of the stock. Ieq Capital LLC boosted its stake in Alumis by 4.1% during the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after buying an additional 690 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after buying an additional 979 shares in the last quarter. Strs Ohio increased its stake in Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares during the last quarter. ProShare Advisors LLC increased its stake in Alumis by 12.4% in the 4th quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after acquiring an additional 1,618 shares during the last quarter. Finally, KBC Group NV purchased a new stake in shares of Alumis during the 1st quarter worth approximately $42,000.

Trending Headlines about Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Institutional ownership has generally increased, including a significant expansion of Geode Capital Management’s position and additional buying by Goldman Sachs, Rhumbline Advisers and other investors. Such activity may provide some support for Alumis shares, although the reported purchases occurred in prior quarters.
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating on ALMS and maintained a $25 price target, suggesting the firm does not currently see a catalyst strong enough to support a more bullish outlook. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six insiders collectively sold 14,953 shares of Alumis at an average price of $26.37, generating approximately $394,311. Sellers included CFO John R. Schroer, whose position fell 11.72%, along with Mark Christopher Bradley, Jorn Drappa, David M. Goldstein, Roy C. Hardiman and Sanam Pangali. The transactions reduced individual holdings by roughly 1.28% to 12.28% and could weigh on investor sentiment because of the concentration of sales. However, insider sales can also reflect personal financial planning rather than a change in the company’s outlook. Alumis Insider Sale Filings
• Negative Sentiment: Alumis remains a clinical-stage biotechnology company with substantial losses. Its latest quarterly results missed both earnings and revenue expectations, while analysts forecast a full-year loss of approximately $2.87 per share. This limits fundamental support until the company reports meaningful clinical or development progress.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.